anti-CD20/CD30-CAR-T
/ Tongji University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 25, 2024
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
New P1 trial • Hematological Malignancies • Lymphoma • Oncology
1 to 1
Of
1
Go to page
1